|
|
Vaccine Detail
|
MUC1 VNTR-Q11 Self-Adjuvanting Tn-Glycopeptide Vaccines |
| Vaccine Information |
- Vaccine Name: MUC1 VNTR-Q11 Self-Adjuvanting Tn-Glycopeptide Vaccines
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MUC1 (Huang et al., 2012)
- Immunization Route: subcutaneous injection
- Description: A fully synthetic, molecularly defined vaccine platform comprising MUC1 VNTR glycopeptides conjugated to self-assembling Q11 peptide domain (QQKFQFQFEQQ). Four vaccine candidates were evaluated: H1 and H2 (Tn glycosylation at PGST motifs), H3 (Tn at Thr in PDTRP), and H4 (dual Tn at Thr in both PDTRP and PGST). The Q11 domain spontaneously aggregates into nanofibers >200 nm long under mild conditions (400 ?M in 6:1 water:PBS, 8h), displaying multivalent B-cell epitopes on fiber surfaces without carrier proteins. Immunization protocol: 4 mice per group, 5 subcutaneous injections (100 nmol in 100 ?L, days 0, 14, 28, 42, 56), sera collected day 63. H3 (PDTRP-only Tn): highest anti-MUC1 IgG titer (6400), significantly elevated IgG2a and IgM with all isotypes detected (IgG1/IgG2b/IgG3), indicating T-cell independent pathway and Th1-type response with CTL activation; antibodies strongly recognized MUC1-expressing MCF-7 human breast cancer cells. H4 (dual PDTRP+PGST Tn): high IgG titers, elevated IgG2a/IgM/all isotypes, MCF-7 recognition, and antisera mediated complement-dependent cytotoxicity against MCF-7 cells. H1/H2 (PGST-only Tn): minimal responses, confirming PDTRP Tn glycosylation is critical for immunogenicity. External Freund's adjuvant nearly eliminated immune responses, indicating self-assembled fibril structure is essential and external emulsion-forming adjuvants destroy critical architecture (Huang et al., 2012).
|
| Host Response |
|
|
| References |
Huang et al., 2012: Huang ZH, Shi L, Ma JW, Sun ZY, Cai H, Chen YX, Zhao YF, Li YM. A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy. Journal of the American Chemical Society. 2012; 134(21); 8730-8733. [PubMed: 22587010].
|
|
